Development of a clinical nomogram for prediction of response to neoadjuvant chemotherapy in patients with advanced gastric cancer

Table 1 Characteristics of patients in the primary and P value of univariate analysis

Characteristics	Obvious response (grade 0/grade 1), n = 95 (%)	Poor response (grade 2/grade 3), n = 135 (%)	t/χ2	P value
Age	59.88 ± 10.00	59.00 ± 11.03	-0.62	0.535
Sex, n
Male	70 (73.68)	84 (62.22)	3.31	0.069
Female	25 (26.32)	51 (37.78)
BMI, kg/m2	22.90 ± 3.55	22.85 ± 2.99	-0.12	0.907
Location
Esophagogastric junction	53 (55.79)	30 (22.22)	27.24	< 0.001
Non-esophagogastric junction	42 (44.21)	105 (77.78)
Tumor size, cm	5.65 ± 2.51	5.97 ± 2.97	0.86	0.393
Tumor differentiation
Well + moderately differentiated	47 (49.47)	38 (28.15)	10.88	0.001
Poorly differentiated + Signet ring cell	48 (50.53)	97 (71.85)
cT stage
T2	6 (6.32)	4 (2.96)	9.64	0.008
T3	34 (35.79)	27 (20.00)
T4	55 (57.89)	104 (77.04)
cN stage
N0	26 (27.37)	24 (17.78)	3.02	0.083
N+	69 (72.63)	111 (82.22)
Blood type
Type A	25 (26.32)	42 (31.11)	0.84	0.840
Type B	27 (28.42)	39 (28.89)
Type AB	11 (11.58)	13 (9.63)
Type O	32 (33.68)	41 (30.37)
CA724, U/mL
≤ 6.5	71 (74.74)	78 (57.78)	7.03	0.008
> 6.5	24 (25.26)	57 (42.22)
CEA, ng/mL
≤ 5	76 (80.00)	102 (75.56)	0.63	0.428
> 5	19 (20.00)	33 (24.44)
CA125, U/mL
≤ 24	82 (86.32)	123 (91.11)	1.32	0.250
> 24	13 (13.68)	12 (8.89)
CA199, U/mL
≤ 30	79 (83.16)	112 (82.96)	0.01	0.969
> 30	16 (16.84)	23 (17.04)
Serum albumin, g/L	41.77 (41.01-42.52)	41.64 (40.98-42.29)	-0.25	0.803
PLT, 109/L	224.56 ± 95.13	214.83 ± 73.90	-0.87	0.384
Lymphocyte, 109/L	1.57 ± 0.51	1.59 ± 0.44	0.25	0.806
PLR	153.65 ± 70.73	144.45 ± 64.21	-1.03	0.306
Neutrophil cell, 109/L	3.65 ± 1.43	3.57 ± 1.36	-0.47	0.637
Monocyte, 109/L	0.43 ± 0.16	0.41 ± 0.14	-1.19	0.235
NMR	9.07 ± 3.98	9.24 ± 3.50	0.346	0.730
NLR	2.29 (2.26-2.73)	2.41 (2.21-2.62)	-0.48	0.629
Smoking history
Yes	36 (37.89)	50 (37.04)	0.02	0.895
No	59 (62.11)	85 (62.96)

6.5 U/mL, 5 ng/mL, 24 U/mL, and 30 U/mL are the normal critical values of carbohydrate antigen 724, carcinoembryonic antigen, carbohydrate antigen 125, and carbohydrate antigen 199 in our hospital, respectively. BMI: Body mass index; CA125: Carbohydrate antigen 125; CA199: Carbohydrate antigen 199; CA724: Carbohydrate antigen 724; CEA: Carcinoembryonic antigen; NLR: Neutrophil to lymphocyte ratio; NMR: Neutrophil to monocyte ratio; PLR: Platelet to lymphocyte ratio; PLT: Platelets.